Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Minnesota Attorney General Lori Swanson wrote to Mayo Clinic CEO and President John Noseworthy, MD, asking the system to pause its consolidation plans in Albert Lea and Austin, Minnesota. Noseworthy, however, said their plans would continue.
The time spent designing and implementing clinical study databases has a negative impact on conducting and completing trials, according to the 2017 eClinical Landscape Study from Tufts Center for the Study of Drug Development.
Smartphone applications may be an effective treatment tool for millions of patients suffering from depression, according to a study published in World Psychiatry. The study examined the safety and effectiveness of mobile apps in patients with various forms of depression.
Care1st Health Plan of Arizona announced its Pacify mobile application program for Medicaid members who are expecting mothers or mothers within a year of giving birth.
Researchers from the University of Michigan have developed a labyrinth chip capable of separating circulating cancer cells from other cells in the body. Explained in Cell System, the chip aims to provide physicians with a tool to personalize cancer treatment and monitor genetic changes.
Group market insurance plans had premiums increase by an average of 3 percent this year, the sixth consecutive year of a single-digit hike and well below the 20 percent jump in non-group market premiums, while employers continue to search for ways to cut costs through different sites of care and wellness programs.
Bring your own device (BYOD) has become increasingly popular as technological security improves. Now, 71 percent of healthcare leaders allow BYOD in some form, according to a recent survey by Spok.
Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.
Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.
When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.